Andere Sprachen Active Biotech AB

Aktien

A0BLFX

SE0001137985

ACTI

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:16:44 29.04.2024			% 5 Tage	% 1. Jan.
0,55 ^SEK	-3,00 %		-1,61 %	+20,48 %

03.04.	Active Biotech AB (publ) gibt den Beginn der Rekrutierung für die klinische Phase I Biodistributionsstudie mit Laquinimod Augentropfen bekannt	CI
08.02.	Active Biotech AB (publ) meldet Ergebnis für das vierte Quartal zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Annual Report 2023 Active Biotech AB (publ)	22.04.
Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops	03.04.
Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	03.04.
Active Biotech Q4 2023 - Three Externally Funded Trials in 2024	09.02.
Active Biotech Year End Report 2023	08.02.
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08.02.
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023	08.02.
Number of shares and votes in Active Biotech	29.12.
Active Biotech provides update on the scheduled clinical program for 2024	22.12.
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024	22.12.
Positive preclinical tasquinimod data presented at ASH 2023 now available on Active Biotech’s website	14.12.
Active Biotech Raises SEK44 Million via Rights Offering	06.12.
Active Biotech announces outcome of the Company’s rights issue	06.12.
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops	06.12.
Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod	05.12.
Active Biotech's nomination committee appointed	01.12.
Active Biotech AB Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee	01.12.
Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis	01.12.
Management and members of the board of directors have subscribed for shares in Active Biotech’s ongoing rights issue	29.11.
Active Biotech publishes prospectus	13.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Active Biotech AB

Aktien

A0BLFX

SE0001137985

ACTI

Andere Sprachen

Filter